Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAF1 | P21675 | 6/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 9/20 | 0.80 |
| ▸ | BRD4 | O60885 | 8/20 | 0.80 |
| ▸ | CECR2 | Q9BXF3 | 6/20 | 0.80 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.67 |
| ▸ | BRD2 | P25440 | 1/20 | 0.67 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.67 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.67 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.67 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.67 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.67 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.67 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749795 | 1.00 | TAF1 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL30073311 | 0.89 | BRD4 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL17749670 | 0.89 | BRD4 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL17749838 | 0.89 | BRD4 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL30073291 | 0.87 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 | |
| SCHEMBL17749745 | 0.87 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 | |
| SCHEMBL17749742 | 0.87 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 | |
| SCHEMBL19640299 | 0.85 | BRD9 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL17749715 | 0.85 | BRD9 (1.00) | TAF1BRD9BRD4CECR2TRIM24 | |
| SCHEMBL17749776 | 0.85 | BRD9 (1.00) | TAF1BRD9BRD4CECR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | claimed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | claimed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | claimed |
| EP-3218375-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218375-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | TAF1 437/4885BRD9 12/4885BRD4 1/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | TAF1 437/4885BRD9 12/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.